Review of Promising Off-Label Use of Deucravacitinib

Area of Science:

• Immunology
• Pharmacology

Background:

• Tyrosine kinase 2 (TYK2) is crucial in inflammatory cytokine signaling (IL-12, IL-23, type I IFNs).
• TYK2 dysregulation is implicated in psoriasis and other immune-mediated diseases.
• Deucravacitinib is an approved oral TYK2 inhibitor for psoriasis with a good safety profile.

Purpose of the Study:

• To review the potential expanded indications for deucravacitinib.
• To explore its therapeutic utility in diverse inflammatory, autoimmune, and other conditions.

Main Methods:

• Review of case reports, clinical trials, and preclinical studies.
• Analysis of diseases involving the TYK2 pathway.
• Assessment of deucravacitinib's reported clinical benefits.

Main Results:

• Deucravacitinib shows clinical benefit in discoid lupus erythematosus, systemic lupus erythematosus, alopecia areata, lichen planus, palmoplantar pustulosis, psoriatic arthritis, systemic sclerosis, interstitial pneumonia, inflammatory bowel disease, and chronic recurrent multifocal osteomyelitis.
• Emerging research suggests potential in Alzheimer's disease, type 1 diabetes, vascular calcification in CKD, T-ALL, and multiple sclerosis.
• Deucravacitinib broadly suppresses cytokine signaling, indicating wide-ranging anti-inflammatory effects.

Conclusions:

• Deucravacitinib's therapeutic potential extends beyond psoriasis to numerous immune-mediated diseases.
• Further clinical trials and mechanistic studies are necessary to confirm efficacy and establish new indications.
• Deucravacitinib represents a promising therapeutic option for a broad spectrum of inflammatory disorders.